A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

PHASE3RecruitingINTERVENTIONAL

Enrollment

430

Participants

Timeline

Start Date

November 27, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

September 30, 2028

Conditions

Colorectal Cancer

Interventions

DRUG

Tucidinostat

30mg orally BIW

DRUG

Sintilimab

200 mg intravenously (IV) Q3W

DRUG

Bevacizumab

7.5mg/kg intravenously (IV) Q3W

DRUG

Fruquintinib

5mg orally QD

Trial Locations (1)

RECRUITING

Rui-Hua Xu, Guangzhou